All relevant data are within the paper and its Supporting Information files. Sequences have been deposited into GenBank, GenBank accession numbers are: KM654599-KM654931, and KM654933-KM654980.

Introduction {#sec001}
============

Influenza viruses belonging to the family Orthomyxoviridae, are classified into influenzavirus A, B, and C. While influenza A and C viruses infect humans and many other species, influenza B viruses only infect humans and seals \[[@pone.0163175.ref001],[@pone.0163175.ref002],[@pone.0163175.ref003]\]. The Influenza virus genome consists of eight negative single-stranded RNA segments encoding eleven proteins: hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), polymerase proteins (PB1, PB2, and PA), matrix proteins (M1 and M2), and nonstructural proteins (NS1 and NS2) \[[@pone.0163175.ref004]\]. Based on reactivity with surface glycoproteins HA and NA, influenza A viruses are classified into eighteen HA subtypes (H1-H18) and eleven NA subtypes (N1-N11) with a total of 144 subtypes possible, while influenza B virus has no subtypes \[[@pone.0163175.ref004],[@pone.0163175.ref005],[@pone.0163175.ref006],[@pone.0163175.ref007],[@pone.0163175.ref008]\]. New influenza viral variants emerge either due to mutations in the virus surface glycoproteins (antigenic drift) or reassortment between viral gene segments from different strains (antigenic shift). While, seasonal influenza outbreaks are thought to arise primarily due to antigenic drift, pandemics are thought to result from complex reassortment events among swine, human, and avian reservoirs. Some of them have been reported to directly infect humans, or transmit avian influenza A viruses from domestic poultry to human \[[@pone.0163175.ref004],[@pone.0163175.ref009],[@pone.0163175.ref010]\]. In addition, influenza viruses normally circulate in pigs are called "variant" viruses when found in people. There was a large outbreak of influenza A(H3N2) variant virus (H3N2v) during the 2010--13 seasons in U.S. and a highly pathogenic avian influenza (HPAI) H5N1 virus was identified in early 2014 in North America \[[@pone.0163175.ref010]\]. According to a USDA report in January 21 2015, HPAI H5N1, H5N2, and H5N8 viruses, which can be potentially transmitted to domestic poultry population leading to an outbreak \[[@pone.0163175.ref011]\], have been detected in U.S. wild birds in the winter of 2015 \[[@pone.0163175.ref012]\]. Identification of H7N9, H10N8 and other viruses in humans outside the U.S. has also been reported \[[@pone.0163175.ref009],[@pone.0163175.ref013]\]. Reassortment of a 2009 H1N1 pandemic influenza A virus (pdH1N1) and influenza A(H3N2) variant virus (H3N2v) with other circulating seasonal strains in the U.S. can produce virus variants with transmissibility and altered virulence for humans \[[@pone.0163175.ref014],[@pone.0163175.ref015]\]. Multiple influenza types/subtypes usually circulate during each season, for example, pdH1N1 were the predominant viruses circulating in December 2013 with fewer influenza B viruses, but influenza B virus became the predominant circulating virus by late March 2014, while seasonal A(H3N2), novel H3N2v, and mixed A/B viruses infections were also identified during the season in the U.S. \[[@pone.0163175.ref016]\].

It was reported that rapid influenza diagnostic tests showed low and variable sensitivity \[[@pone.0163175.ref017],[@pone.0163175.ref018]\] depending on the influenza A subtype \[[@pone.0163175.ref019]\], while some FDA-cleared diagnostic tests did not detect the novel H3N2v viruses \[[@pone.0163175.ref020]\]. Diagnosis of influenza infection from an unknown risk respiratory specimen involves multiple assays \[[@pone.0163175.ref017],[@pone.0163175.ref021]\]. Identification of the first case of A(H5N1) virus infection in North America involved multiple laboratories \[[@pone.0163175.ref010]\]. Current methods that evaluate antiviral resistance require two independent tests for the S31N substitutions conferring amantadine-resistance \[[@pone.0163175.ref022],[@pone.0163175.ref023]\] and the H274Y substitution conferring oseltamivir-resistance \[[@pone.0163175.ref022],[@pone.0163175.ref024]\]. Conventional methods used by diagnostic or reference laboratories for characterization of novel influenza viruses are ineffective since the tests are based on a small conserved region of each HA, NA, and M genes for detection and subtyping, requires the use of many sets of primers, steps and multiple reactions. In addition, this approach may be ineffective for newly emerging influenza subtypes due to mismatch of PCR primers and culture-based genome sequencing which requires high biosafety levels, preventing its application in clinics. Next-generation sequencing (NGS) analysis has been previously reported to greatly improve manipulation procedure for identification of influenza virus strains, these studies focused on examining influenza A \[[@pone.0163175.ref025],[@pone.0163175.ref026],[@pone.0163175.ref027]\] or B \[[@pone.0163175.ref028]\] viruses using cultured virus \[[@pone.0163175.ref027]\], random \[[@pone.0163175.ref027]\], universal \[[@pone.0163175.ref025]\], and multiple \[[@pone.0163175.ref028]\] primers. None of these studies reported the use of a paired set of degenerate universal primers to simultaneously identify whole-genome sequences of influenza A and B viruses from a large set of clinical specimens using an NGS assay. We previously reported development of a genomic nanomicroarray and NGS combination approach for influenza virus screening and laboratory confirmation \[[@pone.0163175.ref029]\]. Here, we extended the NGS approach to potential application for influenza virus surveillance, whole-genome characterization of putative antiviral resistance markers and virulence factors that may confer high virulence in human hosts. We developed a novel universal RT-PCR-NGS platform by testing 162 clinical influenza-positive specimens and demonstrated a "one-size-fits-all" approach to simultaneously identify unknown influenza infections and co-infections in a single tube reaction per sample. The analytical sensitivity of the NGS platform was also evaluated in our studies.

Materials and Methods {#sec002}
=====================

Viruses, Clinical Specimens and Tests {#sec003}
-------------------------------------

Pre-titrated stocks of reference strains of influenza viruses were procured from Dr. Stephen Lindstrom (Centers for Disease Control and Prevention, CDC, Atlanta, GA) or cultured in embryonated chicken eggs at US Food and Drug Administration (FDA). Clinical nasopharyngeal swab specimens were collected from patients with symptoms of influenza-like illness, submitted during the 2010--11 and 2012--13 influenza seasons to the Clinical Virology Laboratory (CVL), Yale New Haven Hospital, New Haven, CT. These specimens were tested as requested by the patients' physicians using a direct fluorescent antibody (DFA) immunoassay (SimulFluor Respiratory Virus Screen Reagent, Millipore, Billerica, MA) and/or by quantitative RT-PCR (RT-qPCR), as previously described \[[@pone.0163175.ref021]\]. A total of 162 nasopharyngeal swab specimens that tested as influenza A- and/or B-positive were de-identified and sent to the Laboratory of Molecular Virology (LMV) at FDA (Institutional Review Board (IRB) approval\# Research Involving Human Subjects Committee (RIHSC):13-048B) for sequencing ([Fig 1](#pone.0163175.g001){ref-type="fig"}). All participants, or their parents or guardians, provided written informed consent when their specimens collected in Yale New Haven Hospital.

![Study profile.\
Enrollment of 162 patients aged 20 months to 89 years with symptoms of influenza-like illness during February 19, 2011 to March 8, 2013 from over twenty cities and towns in Connecticut, and submitted to the Clinical Virology Laboratory (CVL) at Yale New Haven Hospital, New Haven, Connecticut prior to detect by universal RT-PCR and NGS assays at the Laboratory of Molecular Virology (LMV) in FDA. A total of 381 genome sequences identified from 55 specimens including A(H3N2), A(pdH1N1), and Influenza B viruses were submitted into GenBank. DFA, direct fluorescent antigen test; RT-qPCR, quantitative RT-PCR; NGS, next-generation sequencing.](pone.0163175.g001){#pone.0163175.g001}

RNA Extraction and Universal RT-PCR {#sec004}
-----------------------------------

The RNA extraction, some primers, and Reverse Transcription-PCR (RT-PCR) procedures were described previously \[[@pone.0163175.ref029]\] and in [S1 File](#pone.0163175.s004){ref-type="supplementary-material"}. According to previous reports and our testing algorithm using multiple alternative options \[[@pone.0163175.ref029],[@pone.0163175.ref030],[@pone.0163175.ref031],[@pone.0163175.ref032]\], a new set of degenerate universal primers for RT (uniflu, `5’-IAGCARAAGC -3’`) and fusion primers for PCR (unifluF, `5’-ACGACGGGCGACAIAGCARAAGC-3’`; unifluR, `5’-ACGACGGGCGACAAGTAGWAACA-3’`) were designed and tested. The 13bp flanking sequences italicized were added at the 5' end of each PCR primer to enhance the annealing temperature and achieve high fidelity and yield in PCR amplification. These primers target highly conserved regions at the 5\'- and 3\'- terminus of each segment of influenza virus to amplify the whole-genome concomitantly, and have coverage of sequence variants for influenza A, B, and C viruses to achieve improvements in analytical sensitivity and inclusivity.

MiSeq Sequencing {#sec005}
----------------

Sample preparation and bioinformatics data analysis was performed as described \[[@pone.0163175.ref029]\]. Briefly, the concentration of mega-amplicons were measured by using the Qubit dsDNA BR Assay System (Covaris, Woburn, MA, USA), and 1 ng of DNA product was processed for NGS sample preparation by using a Illumina Nextera XT DNA Sample Preparation Kit. Mega-amplicons for each specimen were internally marked with dual-index primers ([S2 Fig](#pone.0163175.s002){ref-type="supplementary-material"}). Up to 96 specimens were barcoded and run in one lane of the sequencer. NGS was performed using a MiSeq v2 kit (500 cycles) to produce 2x250 paired-end reads (Illumina, San Diego, CA). After automated cluster generation in MiSeq, the sequencing was processed and genomic sequence reads obtained.

*De novo* Assembly Strategy {#sec006}
---------------------------

Sequencing reads of approximately 250bp in length were trimmed and the sequence data verified using FastQC software prior to *de novo* assembly. Contigs for individual gene segments from influenza viruses were generated using the *de novo* assembly module on the CLC bio software (v6.0.6, CLC bio, Cambridge, MA). The parameter for mapping reads back to contiguous was set on as similarity fraction 0.9; length fraction 0.5; mismatch cost 2; insertion cost 3 and deletion cost 3. For characterization of influenza whole-genomes with high confidence coverage, minimum contig length was set at 800bp to assemble the consensus sequences and minimum coverage was 1000 reads \[[@pone.0163175.ref033]\]. For diagnosis of influenza virus infections, minimum contig length used was 200bp and higher lengths for 2x reads per base in *de novo* assembly (low confidence coverage, [Fig 1](#pone.0163175.g001){ref-type="fig"} and [S3 Fig](#pone.0163175.s003){ref-type="supplementary-material"}) \[[@pone.0163175.ref034]\].

Bioinformatics Data Analysis {#sec007}
----------------------------

A master file containing all unique contigous sequences of each mega-amplicon was generated and used to perform an all-by-all blast search in Influenza Research Database (IRD, [www.fludb.org](http://www.fludb.org)), the Global Initiative on Sharing All Influenza Data (GISAID, platform.gisaid.org) and NCBI database. The match with the highest score was retained to identify the specific influenza genome. Assembled sequences were aligned by the CLUSTAL W program, and phylogenetic analysis was performed using MEGA 5 and the neighbor-joining method \[[@pone.0163175.ref035]\]. The amino acid sequence for each segment identified was generated and aligned using the Vector NTI Advance package (v·11·5·2, Life Technologies, Grand Island, NY). The serotype and genotype according to the genetic lineage of influenza A viruses were determined using FluGenome \[[@pone.0163175.ref036]\].

Coverage of Depth and Breadth {#sec008}
-----------------------------

The depth of sequence coverage (DOC) was calculated using formulae LN/G, where L is the read length, N is the number of reads and G is the theoretical genome length. The breadth of sequence coverage (BOC) was calculated as percentage of actual testing contig length (≥1000 reads or ≥30x of DOC) divided by the theoretical genome length \[[@pone.0163175.ref034],[@pone.0163175.ref037]\]. Total average length of influenza A and B virus genomes was 13,588bp and 13,559bp, respectively. Representative lengths of individual gene segments from influenza A virus (A/Puerto Rico/8/1934(H1N1)) were as follows; 2341bp (PB2), 2341bp (PB1), 2233bp (PA), 1778bp (HA), 1565bp (NP), 1413bp (NA), 1027bp (M) and 890bp (NS).

Sequence Accession Numbers {#sec009}
--------------------------

The newly reported influenza genome sequences are available in GenBank under the following accession numbers: KM654599-KM654931, and KM654933-KM654980.

Results {#sec010}
=======

NGS Detects Influenza Whole-Genome Segments {#sec011}
-------------------------------------------

To determine the sensitivity of NGS detection, ten-fold serial dilutions of H5N1 viral RNA (1.8x10^9^ TCID~50~/mL) were first produced followed by RT-PCR exponential amplification for whole-genome segments. As shown in [Fig 2A](#pone.0163175.g002){ref-type="fig"}, 10^−7^ dilution of A(H5N1) viral RNA (1.8x10^3^ TCID~50~/mL) was detected in the RT-PCR assay shown as multiple faint visible bands. A total of ten PCR mega-amplicons from the dilutions were next tested using MiSeq, multiple contigs were finally automatically generated for each mega-amplicons, and all contig sequences were correctly identified as genome of A/Viet Nam/1203/2004(H5N1) virus. The overall average of DOC was 4,715. The average of BOC for each identified contig was 96% (≥30x depth) indicating that the near full-length genome sequence was covered ([Table 1](#pone.0163175.t001){ref-type="table"}). Analysis of reads at each dilution level showed that the whole-genome DOC decreases from 4,073 in 10^−1^ dilution to 1,167 in 10^−9^ dilution ([Fig 2B](#pone.0163175.g002){ref-type="fig"}), and the whole-genome BOC decreases from 98% to 11% at the 10^−9^ dilution. We observed that the NP gene (segment 5) represented 99% of BOC at all detected titration points with the lowest detectable level at 10^−9^ dilution (1.8x10^1^ TCID~50~/mL) with high confidence coverage ([Fig 2C](#pone.0163175.g002){ref-type="fig"}).

![**(A) Agarose gel illustrating the sensitivity of the universal RT-PCR assay.** The picture shows PCR mega-amplicons in 2% agarose gel representing the whole-genome segments of A/Viet Nam/1203/2004(H5N1) virus in dilution series, and detection of viral RNA in a dilution of 10^−7^ ([Table 1](#pone.0163175.t001){ref-type="table"}). **(B) Illustrating average depth of coverage (DOC)**. **(C) average breadth of coverage (BOC) in NGS characterization of the influenza genome**.](pone.0163175.g002){#pone.0163175.g002}

10.1371/journal.pone.0163175.t001

###### Length, reads and coverage from serial dilutions of influenza A(H5N1) virus.

![](pone.0163175.t001){#pone.0163175.t001g}

  gene segment (bp)                              serial dilutions                                                                         
  ---------------------------------------------- ------------------ ------- ------- ------- ------- ------- ------- ------ ------- ------ ---
  PB2 (2341)                                     length (bp)        2341    2132    2230    2323    1854    2024    0      0       0      0
  reads (x10^3^)                                 22·3               21·4    17·6    27·2    15·5    29·3    0       0      0       0      
  depth                                          2381               2285    1880    2905    1655    3129    0       0      0       0      
  breadth                                        100%               91%     95%     99%     79%     86%     0%      0%     0%      0%     
  PB1 (2341)                                     length (bp)        2109    2123    2102    2158    1895    1648    2174   0       0      0
  reads (x10^3^)                                 16·2               17·6    13·4    21·7    20·1    15·2    27·7    0      0       0      
  depth                                          1730               1880    1430    2317    2147    1623    2958    0      0       0      
  breadth                                        90%                91%     90%     92%     81%     70%     93%     0%     0%      0%     
  PA (2233)                                      length (bp)        2233    2192    2171    2233    2016    2085    2224   0       0      0
  reads (x10^3^)                                 20                 21·2    16·9    25·9    22·7    39·1    25·5    0      0       0      
  depth                                          2239               2373    1892    2900    2541    4378    2855    0      0       0      
  breadth                                        100%               98%     97%     100%    90%     93%     100%    0%     0%      0%     
  HA (1779)                                      length (bp)        1772    1747    1753    1757    1760    1751    1160   0       0      0
  reads (x10^3^)                                 19·6               20·2    16·7    26·7    29·4    30·6    1·9     0      0       0      
  depth                                          2754               2839    2347    3752    4132    4300    267     0      0       0      
  breadth                                        100%               98%     99%     99%     99%     98%     65%     0%     0%      0%     
  NP (1565)                                      length (bp)        1556    1556    1556    1556    1556    1554    1556   1556    1543   0
  reads (x10^3^)                                 31·4               33·1    27·2    29      34·2    120·5   37·8    19·6   63·3    0      
  depth                                          5016               5288    4345    4633    5463    19249   6038    3131   10112   0      
  breadth                                        99%                99%     99%     99%     99%     99%     99%     99%    99%     0%     
  NA (1398)                                      length (bp)        1371    1389    1398    1398    1389    1389    0      0       0      0
  reads (x10^3^)                                 17·7               17·7    14·4    19·3    21      34·9    0       0      0       0      
  depth                                          3165               3165    2575    3451    3755    6241    0       0      0       0      
  breadth                                        98%                99%     100%    100%    99%     99%     0%      0%     0%      0%     
  M (1027)                                       length (bp)        1027    1016    1027    1003    1016    1027    1027   1018    0      0
  reads (x10^3^)                                 53                 57·1    50·4    53·9    78·1    94·9    86·5    30     0       0      
  depth                                          12902              13900   12269   13121   19012   23101   21056   7303   0       0      
  breadth                                        100%               99%     100%    98%     99%     100%    100%    99%    0%      0%     
  NS (875)                                       length (bp)        884     883     889     891     0       0       0      877     0      0
  reads (x10^3^)                                 40·8               44·1    38·6    45·7    0       0       0       14·4   0       0      
  depth                                          11657              12600   11029   13057   0       0       0       4103   0       0      
  breadth                                        100%               100%    100%    100%    0%      0%      0%      100%   0%      0%     
  Whole Genome (13559)                           length (bp)        13293   13038   13126   13319   11486   11478   8141   3451    1543   0
  reads (x10^3^)                                 221                232·5   195·1   249·3   220·9   364·5   179·3   64     63·3    0      
  depth[\*](#t001fn002){ref-type="table-fn"}     4073               4287    3597    4597    4073    6721    3306    1180   1167    0      
  breadth[\*](#t001fn002){ref-type="table-fn"}   98%                96%     97%     98%     85%     85%     60%     25%    11%     0%     
  No. of genes.                                  8                  8       8       8       7       7       5       3      1       0      

Ten-fold serial dilutions were used in titrations of influenza A(H5N1) virus to establish the analytical sensitivity by universal RT-PCR and NGS assays. Minimum contiguous length sets at 800bp to assemble the consensus sequences for characterization of each segment full-length sequence and minimum coverage is 1000 reads. A calculated whole-genome base of A/Viet Nam/1203/2004 virus is 13559bp.

\* calculation for virus whole-genome.

Molecular Confirmation of Simultaneous Detection of Influenza A and B Viruses in a Single Specimen/Test {#sec012}
-------------------------------------------------------------------------------------------------------

Since some influenza related hospitalized cases were found to be associated with mixed A and B virus co-infections \[[@pone.0163175.ref001],[@pone.0163175.ref016]\], analytical inclusivity studies were performed next by using a new set of degenerate universal primers to achieve improved coverage for varieties of both influenza A and B viruses. We tested A/Fujian Gulou/1896/09(H1N1), A/Perth/16/2009(H3N2), and B/Wisconsin/01/2010 reference viruses. Total RNA was extracted from spiked samples containing either individual or a mixture of two strains 1:1, and RT-PCR was performed. After the NGS test and following *de novo* assembly, eight contigs were generated for A(H1N1), A (H3N2), and B viruses, respectively. Fifteen and sixteen contigs were generated from the mixed A(H1N1), and A(H3N2) with B viruses supported by high confidence coverage, respectively ([S1 Table](#pone.0163175.s005){ref-type="supplementary-material"}). A validation assessment for these contigs from mixed viruses confirmed that the genome sequences are identical to the gene segments of the A(H1N1), A(H3N2), or B viruses, respectively. This is the first report of analytical validation of degenerate universal primers that can simultaneously amplify influenza A and B viruses for NGS identification and discrimination of influenza viruses in a single sample/test.

Detection of Influenza Virus in Nasopharyngeal Swab Specimens {#sec013}
-------------------------------------------------------------

By using the aforementioned strategy, we next tested 162 clinical nasopharyngeal swab specimens ([Fig 1](#pone.0163175.g001){ref-type="fig"}) which previous detection in CVL showed 74%(120/162) DFA test positive, 60%(98/162) RT-qPCR test positive, and 6.2%(10/162) for influenza B viruses. The range of Ct values for the 162 specimens is between 17.4 and 39.2. The PCR mega-amplicons prepared for each of the clinical specimens were analyzed using MiSeq. 99.4%(161/162) specimens detected influenza viral genome (see description below, [S4 Table](#pone.0163175.s008){ref-type="supplementary-material"}). To simplify the table, we reported only 57 isolates with whole-genome segments including 35 A(H3N2) isolates, twelve A(pdH1N1), and ten influenza B viruses identified in NGS data analysis. The results from four different detection methods including DFA, RT-qPCR, universal RT-PCR and NGS assays were summarized in [Table 2](#pone.0163175.t002){ref-type="table"} to represent the types/subtypes for influenza viruses. Results of NGS data analysis representing full-length sequences were listed in [S2 Table](#pone.0163175.s006){ref-type="supplementary-material"}. The average whole-genome DOC for these viruses was between 0.1x10^3^ and 13.7x10^3^, and average whole-genome BOC was between 13% and 100% supporting high confidence coverage.

10.1371/journal.pone.0163175.t002

###### Detection of influenza A and B viruses in nasopharyngeal swab specimens from naturally infected patients collected in the 2010--11 and 2012--13 seasons in Connecticut.

![](pone.0163175.t002){#pone.0163175.t002g}

  Patient ID   Age    Gender   Collected Date   City, State        Detection Methods                     
  ------------ ------ -------- ---------------- ------------------ ------------------- ---------- ------ --------
  Flu003       9      M        12/29/2012       Hamden, CT         B                   B(22·9)    ++?    B
  Flu053       28m.   M        12/30/2012       New Haven, CT      B                   not done   +?     B
  Flu096       9      F        2/5/2013         New Haven, CT      B                   not done   +?     B
  Flu101       72     M        3/5/2013         West Haven, CT     B                   B(21·2)    ++?    B
  Flu103       33     F        3/7/2013         New Haven, CT      B                   not done   +++?   B
  Flu107       23m.   M        3/5/2013         New Haven, CT      B                   not done   +?     B
  Flu108       15     M        3/4/2013         Hamden, CT         B                   B(18·7)    ++?    B
  Flu110       33     F        3/8/2013         New Haven, CT      B                   B(21·4)    ++?    B
  Flu111       11     F        3/8/2013         East Haddam, CT    B                   not done   +?     B
  Flu118       3      M        1/27/2013        West Haven, CT     B                   not done   ++?    B
  Flu042       76     M        12/28/2012       Cheshire, CT       A                   not done   +++    H3N2
  Flu050       79     F        12/29/2012       Essex, CT          A                   A(21·1)    ++++   H3N2
  Flu051       36     F        12/30/2012       New Haven, CT      A                   not done   ++++   H3N2
  Flu055       26     F        12/27/2012       East Haven, CT     A                   not done   ++++   H3N2
  Flu056       62     F        12/30/2012       Clinton, CT        A                   A(24·4)    ++++   H3N2
  Flu060       68     F        12/30/2012       New Haven, CT      A                   not done   ++++   H3N2
  Flu066       29     F        12/30/2012       East Haven, CT     A                   not done   ++     H3N2
  Flu068       84     M        12/29/2012       Hamden, CT         A                   A(17·9)    ++++   H3N2
  Flu072       28     M        12/29/2012       New Haven, CT      A                   not done   +++    H3N2
  Flu074       89     M        12/29/2012       West Haven, CT     not done            A(18·0)    ++++   H3N2
  Flu075       47     M        12/30/2012       Killingworth, CT   A                   A(19·2)    ++++   H3N2
  Flu085       71     M        12/31/2012       Branford, CT       A                   not done   ++++   H3N2
  Flu086       71     M        12/31/2012       Branford, CT       A                   not done   +++    H3N2
  Flu090       49     M        1/1/2013         Wallingford, CT    A                   A(17·4)    ++++   H3N2
  Flu098       82     M        2/4/2013         Milford, CT        A                   A(21·8)    +++    H3N2
  Flu099       44     F        1/3/2013         Madison, CT        A                   A(17·9)    ++++   H3N2
  Flu105       20m.   F        3/4/2013         Hamden, CT         A                   not done   ++++   H3N2
  Flu117       61     F        1/25/2013        New Haven, CT      A                   not done   ++++   H3N2
  Flu119       6      M        1/24/2013        Shelton, CT        not done            A(20·2)    ++++   H3N2
  Flu122       85     F        1/27/2013        Bridgeport, CT     A                   not done   ++++   H3N2
  Flu124       56     F        1/25/2013        New Haven, CT      A                   not done   +++    H3N2
  Flu135       14     F        1/28/2013        North Haven, CT    A                   not done   ++++   H3N2
  Flu138       22m.   M        1/30/2013        New Haven, CT      A                   A(19·5)    ++++   H3N2
  Flu139       7      M        2/1/2013         Derby, CT          A                   not done   ++++   H3N2
  Flu140       16     M        1/29/2013        New Haven, CT      A                   not done   ++++   H3N2
  Flu141       56     M        1/28/2013        New Haven, CT      A                   not done   ++++   H3N2
  Flu146       44     F        2/8/2013         New Haven, CT      A                   A(23·1)    ++++   H3N2
  Flu147       6      F        2/1/2013         New Haven, CT      A                   not done   ++++   H3N2
  Flu159       84     M        2/10/2013        Hamden, CT         A                   A(18·0)    ++++   H3N2
  Flu166       37     F        1/26/2013        New Haven, CT      A                   A(28·8)    ++++   H3N2
  Flu169       24     F        1/25/2013        West Haven, CT     A                   A(25·4)    ++++   H3N2
  Flu170       66     M        1/25/2013        West Haven, CT     not done            A(19·4)    ++++   H3N2
  Flu175       39     M        1/25/2013        New Haven, CT      A                   A(28·5)    \-     H3N2
  Flu177       84     F        1/27/2013        New Haven, CT      A                   A(27·5)    \-     H3N2
  Flu178       39     M        1/31/2013        Hamden, CT         A                   not done   ++++   H3N2
  Flu100       39     M        2/5/2013         Meriden, CT        not done            A(23·9)    +++    pdH1N1
  Flu113       42     F        1/25/2013        West Haven, CT     A                   not done   ++++   pdH1N1
  Flu150       39     M        2/6/2013         Meriden, CT        A                   not done   ++++   pdH1N1
  Flu161       61     F        1/31/2013        Hamden, CT         A                   not done   ++++   pdH1N1
  Flu165       8      M        1/30/2013        North Haven, CT    A                   not done   ++++   pdH1N1
  Flu182       55     M        4/7/2011         New Haven, CT      A                   A          ++++   pdH1N1
  Flu183       76     F        3/7/2011         West Haven, CT     not done            A          +++    pdH1N1
  Flu184       30     F        2/22/2011        Old Lyme, CT       not done            A          +++    pdH1N1
  Flu186       55     M        2/19/2011        Naugatuck, CT      not done            A          +++    pdH1N1
  Flu187       81     F        2/23/2011        New Haven, CT      A                   A          ++++   pdH1N1
  Flu188       10     M        2/28/2011        Stamford, CT       A                   A          ++++   pdH1N1
  Flu189       46     M        3/6/2011         New Haven, CT      A                   A          ++++   pdH1N1

Abbreviations: M, male; F, female; m., months; DFA, direct fluorescent antigen test; RT-qPCR, quantitative RT-PCR; Ct, cycle threshold; Inad, inadequate cells for DFA; A, influenza A virus; B, influenza B virus; "+", universal PCR positive in agarose gel assay for influenza A virus; "-", universal PCR negative in agarose gel assay; "?", PCR positive with different pattern from influenza A virus.

NGS Assay Shows High Detection Sensitivity {#sec014}
------------------------------------------

When we evaluated analytical sensitivity of the NGS method and compared it with other clinical tests ([S3 Table](#pone.0163175.s007){ref-type="supplementary-material"}), the criteria of minimum coverage length of 200bp and more than 2 reads was used to assemble contigs mapping to the influenza genome. Both M (278bp/810 reads) and NS (716bp/16 reads) genes were identified at the 10^−10^ dilution level in the reference H5N1 strain indicating highly sensitive detection. Likewise, we further re-analyzed ten universal RT-PCR negative specimens and 19 universal RT-PCR positive but NGS negative specimens when using the criteria of minimum coverage length of 800bp and 1000 reads ([Fig 1](#pone.0163175.g001){ref-type="fig"}). The NGS data showed that multiple partial influenza genomic sequences were identified in each of 28 specimens representing different influenza genomic profiles ([S3 Table](#pone.0163175.s007){ref-type="supplementary-material"}) and confirmed the presence of 24 A(H3N2) and two A(pdH1N1) infections. There were two cases identified as A(H3N2) and A(pdH1N1) viruses co-infections (Flu087 and Flu185). The specimen Flu175 contained full-length segments for M (1033bp/3033 reads) and NS genes (920bp/1203 reads), while Flu177 contained full-length gene sequence for the M gene (1031bp/3645 reads).

Overall Reporting of Influenza A and B Virus Infections {#sec015}
-------------------------------------------------------

A total of 27.4 million sequence reads representing a total length of 1.73 million base-pairs were obtained from 162 clinical specimens that were processed ([S4 Table](#pone.0163175.s008){ref-type="supplementary-material"}). Of these, approximately 26 million reads (95%) matched the influenza virus genome representing 78% of total read length with an average of 30,000 reads per contig from a total of 867 contigs. 99.4% (161/162) of specimens were identified to contain influenza genomes and their types/subtypes were determined. Among the influenza positive specimens, 83.3% (135/162) were seasonal A(H3N2), 8.6% (14/162) were A(pdH1N1), and 6.2% (10/162) were influenza B viruses. Two cases (1.2%) were identified as A(H3N2) and A(pdH1N1) virus co-infections, and influenza genome was not found in specimen Flu199. Among 123 influenza A viruses with whole-genome sequence data supported by high confidence reads ([S5 Table](#pone.0163175.s009){ref-type="supplementary-material"}), we obtained 83.6% (823/8 x123) contigs in total. The highest DOC and BOCs were observed for the HA, NP, NA, M, and NS genes with each demonstrating 99--100% coverage. The minimum average DOC observed for the PB1 gene was 1,467. The frequency of being detected by the RT-PCR-NGS assay was highest for gene segment M, followed by NS, NP, PA, NA, HA, PB1, and PB2. Genotype results and representative phylogenetic trees for HA, NA, and M genes are described in [S1 Fig](#pone.0163175.s001){ref-type="supplementary-material"}. The details of key signature amino-acid mutations from 47 selected influenza A viruses are summarized in [Table 3](#pone.0163175.t003){ref-type="table"}, The molecular biomarkers for pandemic risk, drug-resistant-, transmission-associated signature mutations, and virulence factors were assessed and further described in the discussion section. We concluded that we have simultaneously and correctly identified genetically distinct lineages of influenza A(H3N2 and pdH1N1) and B viruses in clinical specimens.

10.1371/journal.pone.0163175.t003

###### Comparison of the amino-acid substitutions in the proteins of 47 influenza A(H3N2, and pdH1N1) viruses.

![](pone.0163175.t003){#pone.0163175.t003g}

  Strain               Subtype   PB2       PB1       PA        NP        NA        M2        NS1                                                                   
  -------------------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
  Flu042               H3N2      S         M         ***K***   K         ***A***   ***R***   ***N***   V         ***V***   ***Y***   I         N         ***N***   D
  Flu050               H3N2      S         M         ***K***   K         ***A***   K         S         ***I***   ***V***   ***Y***   I         N         ***N***   D
  Flu051               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu055               H3N2      S         M         ***K***   K         ***A***   ***R***   ***N***   V         ***V***   ***Y***   I         N         ***N***   D
  Flu056               H3N2      S         M         ***K***   K         ***A***   K         S         ***I***   ***V***   ***Y***   I         N         ***N***   D
  Flu060               H3N2      S         ***L***   ***K***   K         ***A***   ***R***   S         ***I***   ***V***   ***Y***   I         N         ***N***   D
  Flu066               H3N2      S         ***L***   ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu068               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu072               H3N2      S         ***L***   ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu074               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu075               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu085               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu086               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu090               H3N2      S         ***L***   ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu098               H3N2      S         M         ***K***   K         ***A***   ***R***   S         ***I***   ***V***   ***Y***   I         N         ***N***   D
  Flu099               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu105               H3N2      S         ***L***   ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu117               H3N2      S         ***L***   ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu119               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu122               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu124               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu135               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu138               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu139               H3N2      S         M         ***K***   K         ***A***   ***R***   ***N***   V         ***V***   ***Y***   I         N         ***N***   D
  Flu140               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu141               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu146               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu147               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu159               H3N2      S         M         ***K***   K         ***A***   ***R***   ***N***   V         ***V***   ***Y***   I         N         ***N***   D
  Flu166               H3N2      S         ***L***   ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu169               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu170               H3N2      S         M         ***K***   K         ***A***   K         S         ***I***   ***V***   ***Y***   I         N         ***N***   D
  Flu175               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu177               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu178               H3N2      S         M         ***K***   K         ***A***   ***R***   S         V         ***V***   ***Y***   I         N         ***N***   D
  Flu100               pdH1N1    ***A***   ***L***   E         ***R***   \-        ***R***   ***N***   ***I***   ***S***   R         ***T***   ***S***   ***N***   D
  Flu113               pdH1N1    ***A***   ***L***   E         ***R***   ***I***   ***R***   ***N***   ***I***   ***S***   R         ***T***   ***S***   ***N***   D
  Flu150               pdH1N1    ***A***   ***L***   E         ***R***   V         ***R***   ***N***   ***I***   ***S***   R         ***T***   ***S***   ***N***   D
  Flu161               pdH1N1    ***A***   ***L***   E         ***R***   ***I***   ***R***   ***N***   ***I***   ***S***   R         ***T***   ***S***   ***N***   D
  Flu165               pdH1N1    ***A***   ***L***   E         K         \-        ***R***   ***N***   ***I***   ***S***   R         T         ***S***   ***N***   D
  Flu182               pdH1N1    ***A***   ***L***   E         ***R***   V         ***R***   ***N***   ***I***   ***S***   R         ***T***   N         ***N***   D
  Flu183               pdH1N1    ***A***   ***L***   E         ***R***   V         ***R***   ***N***   ***I***   ***S***   R         ***T***   ***S***   ***N***   D
  Flu184               pdH1N1    ***A***   ***L***   E         ***R***   V         ***R***   ***N***   \-        ***S***   R         ***T***   ***S***   ***N***   D
  Flu186               pdH1N1    ***A***   ***L***   E         ***R***   V         ***R***   ***N***   ***I***   ***S***   R         ***T***   ***S***   ***N***   D
  Flu187               pdH1N1    ***A***   ***L***   E         ***R***   \-        ***R***   ***N***   ***I***   ***S***   R         ***T***   ***S***   ***N***   D
  Flu188               pdH1N1    ***A***   ***L***   E         ***R***   \-        ***R***   ***N***   ***I***   ***S***   R         ***T***   N         ***N***   D
  Flu189               pdH1N1    ***A***   ***L***   E         ***R***   V         ***R***   ***N***   ***I***   ***S***   R         ***T***   ***S***   ***N***   D
  A/California/04/09   pdH1N1    ***A***   ***L***   E         ***R***   V         ***R***   ***N***   V         ***S***   R         ***T***   ***S***   ***N***   D
  A/Panama/07/99       H3N2      S         M         ***K***   K         ***A***   ***R***   ***N***   V         ***V***   ***Y***   I         N         S         D
  A/Alberta/01/2014    H5N1      ***A***   ***L***   E         ***R***   V         K         S         ***R***   ***S***   R         T         ***S***   S         ***E***

The reference sequences are based on the inspection of amino-acids found in the majority of human pdH1N1, H3N2, and H5N1 viruses. The human-specific substitution residues were highlighted in bold and italic. A dashed line indicates that a space was inserted in the sequence to preserve the alignment.

Discussion {#sec016}
==========

We performed NGS as part of a new detection platform for diagnosis of influenza virus infections using clinical specimens. A method for identification and discrimination of functional significance of diverse influenza viruses has been established. We report (i) multiplexed detection and simultaneous discrimination of influenza virus infections in nasopharyngeal swabs and identification of genetically distinct lineages of influenza A(H3N2 and pdH1N1) and B viruses in a single sequencing run, (ii) identification of influenza virus co-infections in a single specimen/test, (iii) development of new degenerate universal primer pairs for identification of influenza viruses and demonstration of highly sensitive detection of influenza virus infections using the NGS assay. We proposed a "one-size-fits-all" approach using an NGS diagnostic platform for extensive identification of a broad range of influenza virus infections including co-infections, by revealing their comprehensive genetic context and providing matrix reporting information for final sequence-based confirmation.

A total of 162 influenza-positive de-identified nasopharyngeal swab specimens collected from patients in the Connecticut were tested in a blinded fashion using the RT-PCR-NGS platform. No reassortants were found but multiple mutations were detected in the specimens tested. Sequence analysis of 123 influenza A viruses revealed that 66.7%(82/123) of A(H3N2) viruses had a single signature mutation of E627K in the PB2 protein, and 88%(108/123) of influenza A(H3N2 and pdH1N1) viruses contained the S31N mutation in the M2 protein. A mutation of PB2 E627K has been reported to confer high virulence to the virus by enhancing replication efficiency, and increasing polymerase activity and disease severity of avian influenza viruses in mammals \[[@pone.0163175.ref038]\]. The S31N mutation in the transmembrane region of the M2 protein confers resistance to amantadine \[[@pone.0163175.ref009],[@pone.0163175.ref039]\]. The emergence of E627K(PB2) and S31N(M2) mutations raise concerns of increased human disease severity. Influenza viruses contain multi-basic amino-acid motif at the proteolytic cleavage site of HAs, which is associated with broad tissue tropism and organ dissemination and determines viral pathogenicity \[[@pone.0163175.ref040]\]. Investigation of HAs in tested specimens showed a single arginine that appeared at the site (PSIQSR↓G) in A(pdH1N1) and (PEKQTR↓G) in A(H3N2) viruses, suggesting that these viruses belonged to a low pathogenic strain that poses less risk to humans.

We aligned all protein sequences of 47 influenza A viruses and compared their sequences with those in humans that have been reported as amino-acid signatures in past influenza outbreaks ([Table 3](#pone.0163175.t003){ref-type="table"}). The emergence of zanamivir- and oseltamivir-resistant viruses is facilitated by mutations in the NA protein, which provides a major target for developing anti-influenza drugs \[[@pone.0163175.ref041],[@pone.0163175.ref042]\]. Sequence analysis revealed that the E119V signature mutations in these specimens may be susceptible to oseltamivir in A(H3N2) but not in A(pdH1N1) viruses. Three signature residues in the PA protein, PA-100A, PA-356A, and PA-409N, were reported in most H1N1, H2N2, H3N2 or H5N1 strains and could cause pandemics \[[@pone.0163175.ref043]\]. A mammalian-adapting V100A substitution was identified in most A(H3N2) but not in A(pdH1N1) viruses, and S409N was identified in all A(pdH1N1) and some A(H3N2) viruses, indicating their pandemic potential. NP protein plays an important role in viral RNA replication and cross-species transmission \[[@pone.0163175.ref044]\]. An amino-acid signature, valine at position NP-100 reported in 2009 pandemic H1N1 strain \[[@pone.0163175.ref045]\], was found as V100I mutation in all A(pdH1N1) and five A(H3N2) viruses, suggesting genetic changes of influenza A viruses in the 2012--13 seasons in this region. Influenza B virus is typically considered a mild disease and has been causing 20% to 50% of total influenza incidence \[[@pone.0163175.ref046]\]. An E105K point mutation at the NA tetramer in influenza B virus was reported leading to reduced susceptibility to NA inhibitor drugs \[[@pone.0163175.ref047]\]. This mutation was not identified in the B viruses tested in current study.

It has been recognized that clinical influenza tests have variable sensitivity and multiple tests may be required for accurate diagnosis. NGS analysis of influenza viruses has been previously reported \[[@pone.0163175.ref025],[@pone.0163175.ref026],[@pone.0163175.ref027],[@pone.0163175.ref028]\]. However, the sensitivity and simultaneous detection of various influenza viruses from a large set of clinical specimens in a single test has not been reported. Our analytical sensitivity study demonstrated that NGS can identify the full-length NP gene of influenza at a 10^−9^ dilution level (1.8x10^1^ TCID~50~/mL) in the characterization study, and detect partial sequences of M and NS genes at 10^−10^ dilution level in the analytical study ([S3 Table](#pone.0163175.s007){ref-type="supplementary-material"}). When we performed universal RT-PCR-NGS assays in the analytical study using specimens with low virus concentrations \[[@pone.0163175.ref021]\], we further confirmed that multiple influenza genomic sequences were identified in each of the 28 human specimens demonstrating that NGS based diagnostics can achieve highly sensitive detection equivalent to the clinical RT-qPCR test at low virus concentrations. To determine whether the current NGS platform could detect influenza virus in different vertebrate species in addition to humans, we tested chicken specimens obtained from Egypt and identified A(H5N1) \[[@pone.0163175.ref048]\] and A(H9N2) (unpublished data) subtypes. Influenza C virus infection is not routinely tested in clinical settings, therefore, specimens and reference materials were not evaluated in current study.

Since the degenerate universal primers reported here target conserved sequences for influenza A, B and C viruses, it is anticipated that the current NGS based detection platform would enable detection and accurate characterization of influenza infection including novel, emerging strains and reassortants arising during outbreaks. This platform allows multiplex identification and simultaneous discrimination of functional significance in a single test and provides the whole spectrum of the influenza genome. The method described here will have significant implications from the perspective of screening, monitoring, drug resistance, and vaccine development. These features of the assay will facilitate diagnostics and antiviral treatment in the clinical setting and enhance protection of public health. With the aid of bioinformatics, mathematics and epidemiologic studies, a typical genetic matrix composition from a known, and a novel emerging influenza infection can be determined. Development of an automated assembly and analysis pipeline will help uncover new levels of innovation and efficiency of transferring raw reads to specific genomic identification which will facilitate future use of an NGS diagnostics platform for public health surveillance and in clinical microbiology laboratory \[[@pone.0163175.ref049]\].
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